Protagenic Therapeutics Announces Private Placement of Up to $5 Million

PUBT · 1d ago
Protagenic Therapeutics Announces Private Placement of Up to $5 Million
  • Protagenic Therapeutics announced a private placement providing $1.5 million in upfront gross proceeds from new and existing investors.
  • Full exercise of two series of milestone-linked warrants could raise another $3.5 million, bringing potential gross proceeds to $5 million before fees.
  • Proceeds will fund PT00114's IND-enabling activities, its planned Phase 1/2a generalized anxiety disorder trial, and general corporate purposes.
  • First patient dosing is targeted for the second quarter of 2027, subject to FDA review of the IND.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611110830ACCESSWRNAPR_____1249774) on November 11, 2026, and is solely responsible for the information contained therein.